Overview
Practical Utility of Biomarkers in Drug Discovery and Development covers all aspects of biomarker research applied to drug discovery and development and contains state-of-the-art appraisals on the practical utility of genomic, biochemical, and protein biomarkers. Case histories and lessons from successful and unsuccessful applications of biomarkers are included along with key chapters on GLP validation, safety biomarkers and proteomics biomarkers. Regulatory agency perspectives and initiatives both in the US and internationally are also discussed.
Full Product Details
Author: J. Andrew Williams ,
Richard Lalonde ,
Jeffrey R. Koup ,
David D. Christ
Publisher: John Wiley & Sons Inc
Imprint: John Wiley & Sons Inc
Dimensions:
Width: 16.40cm
, Height: 2.80cm
, Length: 24.10cm
Weight: 0.721kg
ISBN: 9780470170830
ISBN 10: 0470170832
Pages: 416
Publication Date: 19 April 2012
Audience:
Professional and scholarly
,
Professional & Vocational
Format: Hardback
Publisher's Status: Active
Availability: Out of stock
The supplier is temporarily out of stock of this item. It will be ordered for you on backorder and shipped when it becomes available.
Reviews
The ability to correlate in vitro and in vivo biomarker information in the process of drug discovery and development lies at the heart of translational research. The goal is to rapidly translate basic discoveries into clinical applications. This book provides state-of-the-art information on this exciting new research approach. (Doody's, 8 February 2013) The text is packed with interesting, comprehensive, and pertinent information, clearly presented with salient points reinforced by inclusion in text boxes ... This is an admirable textbook for those dealing with drug discovery and development. I enjoyed reading through it and I would recommend it to anyone who has an interest, or is developing an interest, in the field of biomarkers and their, as yet, unfulfilled potential. (ISSX International Society for the Study of Xenobiotics, 1 December 2012)
<p> The ability to correlate in vitro and in vivo biomarker information in the process of drug discovery and development lies at the heart of translational research. The goal is to rapidly translate basic discoveries into clinical applications. This book provides state-of-the-art information on this exciting new research approach. (Doody s, 8 February 2013) <p> The text is packed with interesting, comprehensive, and pertinent information, clearly presented with salient points reinforced by inclusion in text boxes ... This is an admirable textbook for those dealing with drug discovery and development. I enjoyed reading through it and I would recommend it to anyone who has an interest, or is developing an interest, in the field of biomarkers and their, as yet, unfulfilled potential. (ISSX International Society for the Study of Xenobiotics, 1 December 2012)
<p> The ability to correlate in vitro and in vivo biomarkerinformation in the process of drug discovery and development liesat the heart of translational research. The goal is to rapidlytranslate basic discoveries into clinical applications. This bookprovides state-of-the-art information on this exciting new researchapproach. (Doody s, 8 February 2013) <p> The text is packed with interesting, comprehensive, andpertinent information, clearly presented with salient pointsreinforced by inclusion in text boxes ... This is an admirabletextbook for those dealing with drug discovery and development. Ienjoyed reading through it and I would recommend it to anyone whohas an interest, or is developing an interest, in the field ofbiomarkers and their, as yet, unfulfilled potential. (ISSX International Society for the Study of Xenobiotics, 1December 2012)
The text is packed with interesting, comprehensive, and pertinent information, clearly presented with salient points reinforced by inclusion in text boxes ... This is an admirable textbook for those dealing with drug discovery and development. I enjoyed reading through it and I would recommend it to anyone who has an interest, or is developing an interest, in the field of biomarkers and their, as yet, unfulfilled potential. ( ISSX International Society for the Study of Xenobiotics , 1 December 2012)
Author Information
J. Andrew Williams, PHD, is Director of Translational Oncology at Pfizer Oncology. Richard Lalonde, PharmD, is Vice President and Global Head of Clinical Pharmacology at Pfizer. Jeffrey Koup, PharmD, is a consultant for PKPD modeling and the owner of Lakeside PKPD, LLC. David D. Christ, PHD, is a consultant with SNC Partners LLC.
